Alex Goldberg

Crocs, Inc. (NASDAQ:CROX) and NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/12/2014 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Crocs, Inc. (NASDAQ:CROX) and NPS Pharmaceuticals, Inc. (NASDAQ:NPSP).

Crocs, Inc. (NASDAQ:CROX) a company that together with its subsidiaries, engages in the design, manufacture, marketing, and distribution of footwear, apparel, and accessories for men, women, and children in the Americas, Europe, and Asia is currently up (+1.74%) on 1,006,279 shares traded. Crocs, Inc. (NASDAQ:CROX) is currently up (+33.78%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Crocs, Inc. (NASDAQ:CROX)

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide is currently up (+2.51%) on 1,140,692 shares traded. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is currently up (+421.9%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com